Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue

References

• Akhtar N, Rehman MU, Khan HMS, et al. (2011). Penetration enhancing effect of polysorbate 20 and 80 on the in vitro percutaneous absorption of l-ascorbic acid. Trop J Pharm Res 10:281–8
   Web of Science ®Google Scholar
• Amani A, York P, de Waard H, Anwar J. (2011). Molecular dynamics simulation of a polysorbate 80 micelle in water. Soft Matter 7:2900–8
   Web of Science ®Google Scholar
• Campisi G, Paderni C, Saccone R, et al. (2010a). Human buccal mucosa as an innovative site of drug delivery. Curr Pharm Des 16:641–52
   PubMed Web of Science ®Google Scholar
• Campisi G, Giannola LI, Florena AM, et al. (2010b). Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: a trial on pigs. J Control Release 145:214–20
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Nagaich U, Gulati N, et al. (2012). Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: a recent review. J Adv Pharm Educ Res 2:32–67
   Google Scholar
• Contin M, Martinelli P. (2010). Pharmacokinetics of levodopa. J Neurol 257:253–61
   PubMed Web of Science ®Google Scholar
• De Caro V, Giandalia G, Siragusa MG, et al. (2008). Evaluation of galantamine transbuccal absorption by reconstituted human oral epithelium and porcine tissue as buccal mucosa models: part I. Eur J Pharm Biopharm 70:869–73
   PubMed Web of Science ®Google Scholar
• De Caro V, Giandalia G, Siragusa MG, et al. (2012). New perspectives in treatment of Parkinson's disease: studies on permeation of ropinirole through buccal mucosa. Int J Pharm 429:78–83
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Sozio P, Cerasa LS. (2008). Antiparkinson prodrugs. Molecules 13:46–68
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. (2007). Projected number of people with Parkinson’s disease in the most populous nations, 2005 through 2030. Neurology 68:384–6
   PubMed Web of Science ®Google Scholar
• Dutton J, Copeland LG, Ptayfer JR, Roberts NB. (1993). Measuring l-Dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with l-Dopa and a dopa decarboxylase inhibitor. Clin Chem 39:629–34
   PubMed Web of Science ®Google Scholar
• Gal JY, Fovet Y, Adib-Yadzi M. (2001). About a synthetic saliva for in vitro studies. Talanta 53:1103–15
   PubMed Web of Science ®Google Scholar
• Giannola LI, De Caro V, Giandalia G, et al. (2008). Synthesis and in vitro studies on a potential dopamine prodrug. Pharmazie 63:704–10
   PubMed Web of Science ®Google Scholar
• Giannola LI, Paderni C, De Caro V, et al. (2010). New prospectives in the delivery of galantamine for elderly patients using the IntelliDrug intraoral device: in vivo animal studies. Curr Pharm Des 15:653–9
   Google Scholar
• Goole J, Amighi K. (2009). Levodopa delivery systems for the treatment of Parkinson’s disease: an overview. Int J Pharm 380:1–15
   PubMed Web of Science ®Google Scholar
• Herrlich S, Spieth S, Nouna R, et al. (2011). Ambulatory treatment and telemonitoring of patients with Parkinson’s disease. In: Wichert R, Eberhardt B, eds. Ambient assisted living. Advanced technologies and societal change series. Berlin: Springer, 295–305
   Google Scholar
• Herrlich S, Spieth S, Messner R, Zengerle R. (2012). Osmotic micropumps for drug delivery. Adv Drug Deliv Rev 64:1617–27
   PubMed Web of Science ®Google Scholar
• Itoh S, Oo C. (2010). A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats. J Pharm Sci 99:227–33
   PubMed Web of Science ®Google Scholar
• Jenner P, McCreary AC, Scheller DKA. (2011). Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression. J Neural Transm 118:1691–702
   PubMed Web of Science ®Google Scholar
• Kankkunen T, Huupponen I, Lahtinen K, et al. (2002). Improved stability and release control of levodopa and metaraminol using ion-exchange fibers and transdermal iontophoresis. Eur J Pharm Sci 16:273–80
   PubMed Web of Science ®Google Scholar
• Kao HD, Traboulsi A, Itoh S, et al. (2000). Enhancement of the systemic and CNS specific delivery of l-Dopa by nasal administration of its water soluble prodrugs. Pharm Res 17:978–84
   PubMed Web of Science ®Google Scholar
• Kulkarni U, Mahalingam R, Pather I, et al. (2010). Porcine buccal mucosa as in vitro model: effect of biological and experimental variables. J Pharm Sci 99:1265–77
   PubMed Web of Science ®Google Scholar
• Meng-Lund E, Marxen E, Pedersen AML, et al. (2014). Ex vivo correlation of the permeability of metoprolol across human and porcine buccal mucosa. J Pharm Sci 103:2053–61
   PubMed Web of Science ®Google Scholar
• Mercuri NB, Bernardi G. (2005). The “magic” of l-dopa: why is it the gold standard Parkinson’s disease therapy? Trends Pharmacol Sci 26:341–4
   PubMed Web of Science ®Google Scholar
• Moffat AC, Osselton MD, Widdop B, eds. (2004). Clarke’s analysis of drugs and poisons and identification of drugs. 3rd ed. London: The Pharmaceutical Press, 1172
   Google Scholar
• Notman R, Anwar J. (2013). Breaching the skin barrier – insights from molecular simulation of model membranes. Adv Drug Deliv Rev 65:237–50
   PubMed Web of Science ®Google Scholar
• Paderni C, Campisi G, Schumacher A, et al. (2013). Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects. Int J Pharm 452:128–34
   PubMed Web of Science ®Google Scholar
• Pahwa R, Lyons KE. (2011). Current issues in the diagnosis and treatment of Parkinson’s disease. Introduction. Int J Neurosci 121:1–2
   PubMed Web of Science ®Google Scholar
• Patel VF, Liu F, Brown MB. (2011). Advances in oral transmucosal drug delivery. J Control Release 153:106–16
   PubMed Web of Science ®Google Scholar
• Rai V, Tan HS, Michniak-Kohn B. (2011). Effect of surfactants and pH on naltrexone (NTX) permeation across buccal mucosa. Int J Pharm 411:92–7
   PubMed Web of Science ®Google Scholar
• Rao SS, Hofmann LA, Shakil A. (2006). Parkinson’s disease: diagnosis and treatment. Am Fam Physician 74:2047–54
   Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Quinn ME (eds). (2009). Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press, 551–3
   Google Scholar
• Scholz OA, Wolff A, Schumacher A, et al. (2008). Drug delivery from the oral cavity: focus on a novel mechatronic delivery device. Drug Discov Today 13:247–53
   PubMed Web of Science ®Google Scholar
• Senel S, Rathbone MJ, Cansız M, Pather I. (2012). Recent developments in buccal and sublingual delivery systems. Exp Opin Drug Del 9:615–28
   PubMed Web of Science ®Google Scholar
• Thackaberry EA, Kopytek S, Sherratt P,et al. (2010). Comprehensive investigation of hydroxypropyl methylcellulose, propylene glycol, polysorbate 80, and hydroxypropyl-beta-cyclodextrin for use in general toxicology studies. Toxicol Sci 117:485–92
   PubMed Web of Science ®Google Scholar
• Varanese S, Birnbaum Z, Rossi R, Di Rocco A. (2011). Treatment of advanced Parkinson’s disease. Parkinsons Dis 2010:480260. Doi:10.4061/2010/480260, 2010:480260, 9 pages
   PubMed Web of Science ®Google Scholar
• Veuillez F, Kalia YN, Jacques Y, et al. (2001). Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm 51:93–109
   PubMed Web of Science ®Google Scholar
• Wan LSC, Lee PFS. (1974). CMC of polysorbates. J Pham Sci 63:136–7
   PubMed Web of Science ®Google Scholar
• Wang YF, Zuo Z, Chen X, et al. (2010). Improving sublingual delivery of weak base compounds using pH(max) concept: application to propranolol. Eur J Pharm Sci 39:272–8
   PubMed Web of Science ®Google Scholar
• Wright BA, Waters CH. (2013). Continuous dopaminergic delivery to minimize motor complications in Parkinson’s disease. Expert Rev Neurother 13:719–29
   PubMed Web of Science ®Google Scholar
• Zhou T, Hider RC, Jenner P, et al. (2010). Design, synthesis and biological evaluation of l-dopa amide derivatives as potential prodrugs for the treatment of Parkinson’s disease. Eur J Med Chem 45:4035–42
   PubMed Web of Science ®Google Scholar